Novel targets for the treatment of endometriosis

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 5, 2004, Pages 459-471

  Nothnick, Warren B ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Endometriosis; Matrix metalloproteinase (MMP) treatment; TNF

Indexed keywords

11BETA (4 ACETYLPHENYL) 17BETA HYDROXY 17ALPHA (1,1,2,2,2 PENTAFLUOROETHYL)ESTRA 4,9 DIEN 3 ONE; 4 [N (4 BROMOBENZYL) N (1,2,4 TRIAZOL 4 YL)AMINO]BENZONITRILE; ANTIGESTAGEN; AROMATASE INHIBITOR; BUSERELIN; CETRORELIX; CITRATE CALCIUM; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DANAZOL; ESTROGEN; ETANERCEPT; FADROZOLE; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LETROZOLE; LEUPRORELIN; MATRIX METALLOPROTEINASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MIFEPRISTONE; NAFARELIN; NAFARELIN ACETATE; NORETHISTERONE ACETATE; ONAPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR MODULATOR; UNINDEXED DRUG; VITAMIN D;

DEPRESSION; DRUG COST; DRUG MEGADOSE; DRUG RESEARCH; DRUG TARGETING; ENDOMETRIOSIS; FEMALE; FEMALE INFERTILITY; HEADACHE; HOT FLUSH; HUMAN; LIBIDO DISORDER; MENTAL DISEASE; MOOD DISORDER; NONHUMAN; PELVIS PAIN SYNDROME; REMISSION; REVIEW; SIDE EFFECT; VAGINAL DRYNESS; VASOMOTOR DISORDER;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; AROMATASE INHIBITORS; ASCITIC FLUID; CELL ADHESION MOLECULES; CYTOKINES; DRUG DESIGN; ENDOMETRIOSIS; FEMALE; GONADAL STEROID HORMONES; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HORMONE ANTAGONISTS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFERTILITY, FEMALE; LEUPROLIDE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROTEASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 5444224886     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.5.459     Document Type: Review

References (95)

1. HALME J, HAMMOND MG, HULKA JF et al.: Retrograde menstruation in healthy women and in patients with endometriosis. Obstet. Gynecol. (1984) 64:151-154.
2. LIU DT, HITCHCOCK A: Endometriosis: its association with retrograde menstruation, dysmenorrhea, and tubal pathology. Br. J. Obstet. Gynaecol. (1986) 93:859-886.
3. ORAL E, OLIVE DL, ARICI A: The peritoneal environmental in endometriosis. Hum. Reprod. Update (1997) 2:385-398.
4. IWABE T, HARADA T, TSUDO T et al.: Tumor necrosis factor-α promotes proliferation of endometriotic stromal cells by inducing interleukin-8 gene and protein expression. J. Clin. Endocrinol. Metab. (2000) 85:824-829.
5. SILLEM M, PRIFTI S, MONGA B et al.: Integrin-mediated adhesion of uterine endometrial cells from endometriosis patients to extracellular matrix proteins is enhanced by tumor necrosis factor alpha (TNFα) and interleukin-1 (IL-1). Eur. J. Obstet. Gynecol. Reprod. Biol. (1999) 87:123-127.
6. WITZ CA, MONOTOYA-RODRIQUEZ IA, SCHENKEN RS: Whole explants of peritoneum and endometrium: a novel model of the early endometriosis lesion. Fertil. Steril. (1999) 71:56-60.
7. WITZ CA, TAKAHASHI A, MONTOYA-RODRIGUEZ IA et al.: Expression of the α2β1 and αβ1 integrins at the surface of mesothelial cells: a potential attachment site of endometrial cells. Fertil. Steril. (2000) 74:579-584.
8. WITZ CA, THOMAS MR, MONTOYA-RODRIGUEZ IA et al.: Short-term culture of peritoneum explants confirms attachment of endometrium to intact peritoneal mesothelium. Fertil. Steril. (2001) 75:385-390.
9. GAETJE R, KOTZIAN S, HERRMANN G et al.: Invasiveness of endometriotic cells in vitro. Lancet (1995) 346:1463-1464.
10. GORNILLIE FJ, OOSTERLYNCK D, LAUWERYNS JM et al.: Deeply infiltrating pelvic endometriosis: histology and clinical significance. Fertil. Steril. (1990) 53:978-983.
11. SPUIJBROEK MD, DUNSELMAN GA, MENHEERE PP et al.: Early endometriosis invades the extracellular matrix. Fertil. Steril. (1992) 58:929-933.
12. ABBOTT JA, CLAYTON RD, GARRY R: The effects and effectiveness of laparoscopic excision of endometriosis: a prospective study with 2-5 year follow-up. Hum. Reprod. (2003) 9:1922-1927.
13. OLIVE DL, PRITTS EA: The treatment of endometriosis. A review of the evidence. Ann. N Y Acad. Sci. (2002) 955:360-372.
14. MONTGOMERY-RICE V: Conventional medical therapies for endometriosis. Ann. N Y Acad. Sci. (2002) 955:343-352.
15. VALLE RF, SCIARRA JJ: Endometriosis: treatment strategies. Ann. N Y Acad. Sci. (2003) 997:229-239.
16. VERCELLINI P, CORTESI I, CROSIGNANI PG: Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil. Steril. (1997) 68:393-401.
17. FELBERBAUM RE, DIEDRICH K: Gonadotropin hormone-releasing antagonists: will they replace the agonists? Reprod. Biomed. Online (2003) 6:43-53.
18. CLEMENS LE, SITTER PK, STITES DP: Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy. J. Immunol. (1979) 122:1978-1985.
19. SCHUST DJ, ANDERSON DJ, HILL JA: Progesterone-induced immunosuppression is not mediated through the progesterone receptor. Hum. Reprod. (1996) 11:980-985.
20. OSTEEN KG, KELLER NR, FELTUS FA et al.: Paracrine regulation of matrix metalloproteinase expression in the normal endometrium. Gynecol. Obstet. Invest. (1999) 48(Suppl. 1):2-13.
21. HILL JA, BARBIERI RL, ANDERSON DJ: Immunosuppressive effects of danazol in vitro. Fertil. Steril. (1987) 48:414-418.
22. MORI H, NAKAGAWA M, ITOH N et al.: Danazol suppresses the production of interleukin-1β and tumor necrosis factor by human monocytes. Am. J. Reprod. Immunol. (1990) 24:45-50.
23. OTA H, IGARASHI S, HAYAKAWA M et al.: Effect of danazol on the immunocompetent cells in the eutopic endometrium in patients with endometriosis: a multicenter cooperative study. Fertil. Steril. (1996) 65:545-551.
24. WU MY, CHAO KH, CHEN SU et al.: The suppression of peritoneal cellular immunity in women with endometriosis could be restored after gonadotropin releasing hormone agonist treatment. Am. J. Reprod. Immunol. (1996) 35:510-516.
25. CHEN HF, JEUNG EB, STEPHENSON M et al.: Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J. Clin. Endocrinol. Metab. (1999) 84:743-750.
26. HARADA T, ENATSU A, MITSUNARI M et al.: Role of cytokines in progression of endometriosis. Gynecol. Obstet. Invest. (1999) 47(Suppl. 1):34-40.
27. IMAI A, OHNO T, IIDA K et al.: Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol. Oncol. (1994) 55:144-148.
28. IKEDA M, TAGA M, KUROGI K et al.: Gene expression of gonadotropin-releasing hormone, but not its receptor in human endometrium and decidua. Mol. Cell. Endocrinol. (1997) 135:165-168.
29. BORRONI R, DI BLASIO AM, GAFFURI B et al.: Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol. Cell. Endocrinol. (2000) 159:37-43.
30. ADASHI EY: Long-term gonadotropin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms. Hum. Reprod. Update (1994) 7:1380-1397.
31. KIESEL L, SCHWEPPE KW, SILLEM M et al.: Should add-back therapy for endometriosis be deferred for optimal results? Br. J. Obstet. Gynaecol. (1996) 103(Suppl. 14):15-17.
32. SURREY ES: Add-back therapy and GnRH agonist in the treatment of patients with endometriosis: can a consensus be reached? Add-back consensus Working Group. Fertil. Steril. (1999) 71:420-424.
33. WATANABE Y, NAKAMURA G, MATSUGUCHI H et al.: Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women. Fertil. Steril. (1992) 58:66-71.
34. WHEELER JM, KNITTLE JD, MILLER JD: Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. Am. J. Obstet. Gynecol. (1993) 169:26-33.
35. WARNOCK JK, BUNDREN JC, MORRIS DW: Depressive symptoms associated with gonadotropin-releasing hormone agonists. Depress. Anxiety (1998) 7:171-177.
36. RACHMAN M, GARFIELD DA, RACHMAN I et al.: Lupron-induced mania. Biol. Psychiatry (1999) 45:243-244.
37. KUPKER W, FELBERBAUM RE, KRAPP M et al.: Use of GnRH antagonists in the treatment of endometriosis. Reprod. Biomed. Online (2002) 5:12-16.
38. MURPHY AA, ZHOU MH, MALKAPURAM S et al.: RU486-induced growth inhibition of human endometrial cells. Fertil. Steril. (2000) 74:1014-1019.
39. KETTEL LM, MURPHY AA, MORALES AJ et al.: Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil. Steril. (1996) 65:23-28.
40. KETTEL LM, MURPHY AA, MORALES AJ et al.: Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU486). Am. J. Obstet. Gynecol. (1998) 178:1151-1156.
41. STOECKEMANN K, HEGELE-HARTUNG C, CHWALISZ K: Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats. Hum. Reprod. (1995) 10:3264-3271.
42. FUHRMANN U, HESS-STUMMP H, CLEVE A et al.: Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J. Med. Chem. (2000) 43:5010-5016.
43. SLAYDEN OD, CHWALISZ K, BRENNER RM: Reversible suppression of menstruation with progesterone antagonists in rhesus macaques. Hum. Reprod. (2001) 8:1562-1574.
44. NOBLE LS, SIMPSON ER, JOHNS A et al.: Aromatase expression in endometriosis. J. Clin. Endocrinol. Metab. (1996) 81:174-179.
45. BULUN SE, YANG S, FANG Z et al.: Estrogen production and metabolism in endometriosis. Ann. N Y Acad. Sci. (2002) 955:75-85.
46. TAKAYAMA K, ZEITOUN K, GUNBY RT et al.: Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil. Steril. (1998) 69:709-713.
47. AILAWADI RK, JOBANPUTRA S, KATARIA M et al.: Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil. Steril. (2004) 81:290-296.
48. YANO S, IKEGAMI Y, NAKAO K: Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats. Arzneimittelforschung (1996) 46:192-195.
49. KUDOH M, SUSAKI Y, IDEYAMA Y et al.: Inhibitory effects of a novel aromatase inhibitor, YM511, in rats with experimental endometriosis. J. Steroid Biochem. Mol. Biol. (1997) 63:1-3.
50. GOTTSCHALK C, MALBERG K, ARNDT M et al.: Matrix metalloproteinases and TACE play a role in the pathogenesis of endometriosis. Adv. Exp. Med. Biol. (2000) 477:483-486.
51. KOKORINE I, NISOLLE M, DONNEZ J et al.: Expression of interstitial collagenase (matrix metalloproteinase-1) is related to the activity of human endometriotic lesions. Fertil. Steril. (1997) 68:246-251.
52. MIZUMOTO H, SAITO T, ASHIHARA K et al.: Expression of matrix metalloproteinases in ovarian endometriomas: immunohistochemical study and enzyme immunoassay. Life Sci. (2002) 71:259-273.
53. WENZL RJ, HEINZL H: Localization of matrix metalloproteinase-2 in uterine endometrium and ectopic implants. Gynecol. Obstet. Invest. (1998) 45:253-257.
54. CHUNG HW, LEE JY, MOON HS et al.: Matrix metalloproteinase-2, membranous Type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium. Fertil. Steril. (2002) 78:787-795.
55. SAITO T, MIZUMOTO H, KUROKI K et al.: Expression of MMP-3 and TIMP-1 in the endometriosis and the influence of danazol. Nippon Sanka Fujinka Gakkai Zasshi (1995) 47:495-496.
56. CHUNG HW, WEN Y, CHUN SH et al.: Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in ectopic and eutopic endometrium in women with endometriosis: a rationale for endometriotic invasiveness. Fertil. Steril. (2001) 75:152-159.
57. GILABERT-ESTELLES J, ESTELLES A, GILABERT J et al.: Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis. Hum. Reprod. (2003) 18:1516-1522.
58. BRUNER KL, MATRISIAN LM, RODGERS WH et al.: Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions by human endometrium in nude mice. J. Clin. Invest. (1997) 99:2851-2857.
59. BRUNER KL, EISENBERG E, GORSTEIN F et al.: Progesterone and transforming growth factor-β coordinately regulate suppression of endometrial matrix metalloproteinases in a model of experimental endometriosis. Steroids (1999) 64:648-653.
60. BRUNER-TRAN KL, WEBSTER-CLAIR D, OSTEEN KG: Experimental endometriosis: the nude mouse as a xenograft host. Ann. N Y Acad. Sci. (2002) 955:328-339.
61. ORAL E, ARICI A: Pathogenesis of endometriosis. Obstet. Gynecol. Clin. North Am. (1997) 24:219-233.
62. SIDELL N, HAN SW, PARTHASARATHY S: Regulation and modulation of abnormal immune responses in endometriosis. Ann. N Y Acad. Sci. (2002) 955:159-173.
63. GAZVANI R, TEMPLETON A: Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction (2002) 123:217-226.
64. TABIBZADEH S: The signals and molecular pathways involved in human menstruation, a unique process of tissue destruction and remodelling. Mol. Hum. Reprod. (1996) 2:77-92.
65. SILLEM M, PRIFTI S, KOCH A et al.: Regulation of matrix metalloproteinases and their inhibitors in uterine endometrial cells of patients with and without endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. (2001) 95:167-174.
66. D'ANTONIO M, MARTELLI F, PEANO S et al.: Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally induced endometriosis in rats. J. Reprod. Immunol. (2000) 48:81-98.
67. D'HOOGHE TM, NUGENT N, CUNEO S et al.: Recombinant human TNF binding protein (r-hTBP-1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil. Steril. (2001) 76(Suppl. 3):S1.
68. BARRIER BF, BATES GW, LELAND MW et al.: Efficacy of anti-tumor necrosis factor therapy in treatment of spontaneous endometriosis in baboons. Fertil. Steril. 81(Suppl. 1):775-779.
69. VIHINEN P, KAHARI VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer (2002) 99:157-166.
70. NELSON AR, FINGLETON B, ROTHERBERG ML et al.: Matrix metalloproteinases: biological activity and clinical applications. J. Clin. Oncol. (2000) 18:1135-1149.
71. BURBRIDGE MF, COGE F, GALIZZI JP et al.: The role of matrix metalloproteinases during in vitro vessel formation. Angiogenesis (2002) 5:215-226.
72. UNEMORI EN, FERRARA N, BAUER EA, AMENTO EP: Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J. Cell. Physiol. (1992) 153:557-562.
73. ETOH T, INOUE H, TANAKA S et al.: Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. (2001) 61:2145-2153.
74. HIRATSUKA S, MARU Y, OKADA A et al.: Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. (2001) 61:1207-1213.
75. BARCZ E, ROZEWSKA ES, KAMINSKI P et al.: Angiogenic activity and IL-8 concentrations in peritoneal fluid and sera in endometriosis. Int. J. Gynaecol. Obstet. (2002) 79:229-235.
76. MAHNKE JL, DAWOOD MY, HUANG JC: Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis. Fertil. Steril. (2000) 73:166-170.
77. MCLAREN J, PRENTICE A, CHARNOCK-JONES DS, SMITH SK: Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum. Reprod. (1996) 11:220-223.
78. HULL ML, CHARNOCK-JONES DS, CHAN CL et al.: Antiangiogenic agents are effective inhibitors of endometriosis. J. Clin. Endocrinol. Metab. (2003) 88:2889-2899.
79. STEINLEITNER A, LAMBERT H, ROY S: Immunomodulation with pentoxifylline a brogates macrophage-mediated infertility in an in vivo model: a paradigm for a novel approach to the treatment of endometriosis-associated subfertility. Fertil. Steril. (1991) 55:26-31.
80. NOTHNICK WB, CURRY TE, VERNON MW: Immunomodulation of rat endometriotic implant growth and protein production. Am. J. Reprod. Immunol. (1994) 31:151-162.
81. BALASCH J, CREUS M, FABREGUES F et al.: Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial. Hum. Reprod. (1997) 12:2046-2050.
82. WARD A, CLISSOLD SP: Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs (1987) 34:50-97.
83. ALKHARFY KM, KELLUM JA, MATZKE GR: Unintended immunomodulation: part II. Effects of pharmacological agents on cytokine activity. Shock (2000) 13:346-360.
84. MAKSYMOWYCH WP, AVINA-ZUBIETA A, LUONG MH et al.: An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J. Rheumatol. (1995) 22:625-629.
85. REIMUND JM, BUMONT S, MULLER CD et al. In vitro effects of pentoxifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut (1997) 40:475-480.
86. STRIETER RM, REMICK DG, WARD PA et al.: Cellular and molecular regulation of tumor necrosis factor-α by pentoxifylline. Biochem. Biophys. Res. Commun. (1988) 155:1230-1236.
87. SULLIVAN GW, CARPER HT, NOVICK WJ Jr et al.: Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect. Immun. (1988) 56:1722-1729.
88. FOX RI, HERRMANN ML, FRANGOU CG et al.: Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol. (1999) 93:198-208.
89. JARVIS B, FAULDS D: Etanercept: a review of its use in rheumatoid arthritis. Drugs (1999) 57:945-966.
90. MARKHAM A, LAMB HM: Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs (2000) 59:1341-1359.
91. NIKAS SN, DROSOS AA: Onercept. Serono. Curr. Opin. Investig. Drugs (2003) 4:1369-1376.
92. BANG LM, KEATING GM: Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs (2004) 18:121-139.
93. MEZYK R, BZOWAKA M, BERETA J: Structure and functions of tumor necrosis factor-α converting enzyme. Acta Biochim. Pol. (2003) 50:625-645.
94. ZHANG Y, XU J, LEVIN J et al.: Identification and characterization of 4-[[4-(2-butynyloxy)phyenyl]sulfonyl]-N-hydroxy-2, 2-dimethyl-(3S)-thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-α-converting enzyme/matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis. J. Pharmacol. Exp. Ther. (2004) 309:348-355.
95. CONWAY JG, ANDREWS RC, BEAUDET B et al.: Inhibition of tumor necrosis factor-α (TNF-α) production and arthritis in the rate by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases. J. Pharmacol. Exp. Ther. (2001) 298:900-908.